Alternatively, the predominance of HER2 mutant disease aligns with emerging external evidence indicating the superior efficacy of anti-HER2 ADC (T-DXd) in treating HER2-mutant advanced NSCLC during the patient recruitment period for the study. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.